Matt has served as Chief Executive Officer & board member of Oxidien Pharmaceuticals. since April 2022, and has more than thirty years’ experience in the healthcare arena, as both a healthcare and Wall Street executive.
Mr. Duffy has extensive development-to-market experience, beginning at Pfizer, Inc., in 1984, in Sales, Sales Management and Marketing (CNS, Cardiovascular, Anti-Infectives, Metabolic). He subsequently led the efforts to bring several important new drugs to commercialization including Synagis, while head of Marketing at MedImmune, Inc., from 1995 to 2001, and Cinryze, while head of Commercial Operations (Sales, Sales Management, Marketing, Managed Care, Patient Services, Distribution, FDA Advisory Committee preparation) at Lev Pharmaceuticals, Inc. from 2007 to 2008.
More recently, from 2017 to 2018, Mr. Duffy was President, Chief Operating Officer and a member of the Board of Directors of AltMed Enterprises, LLC, a medical cannabis company, where he was instrumental in raising capital; executed an overhaul of the company’s Arizona operation which led to a significant improvement in productivity; launched the company’s first retail dispensary; oversaw the commercial launch of AltMed Florida; restructured the corporate operation and implemented a comprehensive budgeting process.
Mr. Duffy is also a Managing Partner at Laidlaw Venture Partners dba Laidlaw & Company (UK) Ltd. and is part of the Investment Banking Healthcare Team.
